Denosumab 注射藥用於治療骨質疏鬆的腎移植病患

陳思翰1、王華斌1、吳俊賢1

高雄義大醫院 外科部 泌尿科

Effect of Denosumab on osteoporosis in kidney transplant recipients

Sih-Han Chen1、Hua-Pin Wang1、Chun-Hsien Wu1

Divisions of Urology, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan

 

Purpose: We investigate the efficacy of denosumab (60 mg every 6 months for 12 months) to treat post kidney transplantation osteoporosis.

Materials and Methods: A total of 19 post kidney transplant patients who had osteoporosis in accordance with World Health Organization criteria for the definition (T score ≤ −2.5 SD) were included in the study. Post kidney transplant patients undergoing treatment between 2015 and 2018 were enrolled and followed up for one year. They were divided into two groups: denosumab (DNS) group and control group. Lumbar 1-4, total hip and femoral neck BMD levels were measured by a dual-energy X-ray absorptiometry (DXA) at baseline and 12 months. All patients had calcium and vitamin D supplementation.

Results: Nine patients were in the DNS group, and ten patients were in the control group. Total lumbar spine BMD increased in DNS treatment-arm (0.75±0.04 g/cm2 to 0.80±0.05 g/cm2; p=0.017).  Total hip BMD increased in DNS treatment-arm (0.62±0.07 g/cm2 to 0.67±0.06 g/cm2; p=0.011). DNS-administration resulted in higher increase from baseline in total lumbar BMD compared to control group, however, did not reach statistical significance (DNS vs control: 6.16%±5.68 vs 2.1%±5.28, p=0.086).

Conclusions: Our 1- year follow up data indicated that denosumab increased BMD in kidney transplant patients with osteoporosis.

 

    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2019-01-07 13:41:18
    最近修訂
    2019-01-07 13:45:35
    瀏覽
    361
    1. 1.
      Moderated Poster 1
    2. 2.
      Moderated Poster 2
    3. 3.
      Podium 1
    4. 4.
      Podium 2
    5. 5.
      Podium 3
    6. 6.
      NDP